With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Raised in a blue-collar neighborhood of Somerville, MA, Dr Bob Harrington was blessed to have a strong family and the Jesuits on his side as he traveled from "Yankee" Boston to Duke University. Join him as he tells his story to Dr Rob Califf.
How do regulatory pathways differ in the US and UK? Drs Harrington, Bhatt, and Cleland share their experiences and offer insight on how to support innovative research.
Dr Melissa Walton-Shirley talks to Dr Nassir Marrouche about the results of RE-LY, the impact of dronedarone on the treatment of atrial fibrillation, and his hopes for the future of MRI-guided ablation.
Join heartwire's Lisa Nainggolan as she talks to DrsFranz Messerli and Melissa Walton-Shirley about the results of the KYOTO HEART Study, what they mean for North American and European populations, and the future role of angiotensin-receptor blockers (ARBs).
Exactly three years after the DES firestorm ignited the World Congress of Cardiology in Barcelona, heartwire's Shelley Wood sifts through the ashes with Drs Tony Gershlick, Christian Spaulding, and Renu Virmani in a discussion on DES safety and what we've learned since September 2006.
Dr Robert Califf sits down with Drs Alfred Bove, Jack Lewin, and Clyde Yancy and AHA CEO Nancy Brown to talk about the ACC and the AHA and their role in the debate on healthcare reform.
Dr Valentin Fuster returns to the city where he was born for a scintillating discussion with Drs Fox, Gershlick, Marrouche, Messerli, Spaulding, Vergheugt, Virmani, and Yancy about the miracle of RE-LY and the striking success of ticagrelor in the PLATO study.
Join Dr Robert Califf for a probing and personal interview with Dr Steve Nissen, about his activist days at the University of Michigan and the development of IVUS, to how he ended up at the Cleveland Clinic and what he thinks about the future of medicine in America.
With the global trend leaning toward increased use of transradial access, our international panel reports on standard practice at their respective institutions and the key issues that influence it such as bleeding, access-site complications, stroke risk, patient mobility, and operator experience. Join Drs Kandzari (US), Feres (Brazil), Le May (Canada), and Steg (France) for this thoughtful and practical discussion.
Join Drs Valentin Fuster, Anne Curtis, Timothy Gardner, Barry Greenberg, Cindy Grines, Bob Harrington, Sanjay Kaul, Harlan Krumholz, and Salim Yusuf as they unravel the STICH trial and debate the lessons learned from PROTECT-AF in Part 1 of the Cardiology Show. In Part 2 of the program, the JUPITER trial is back on the table and our experts give their opinion on the polypill following the results of the TIPS study.
As theheart.org enters its 10th year join editor-in-chief, Dr Eric Topol, and his guests for a second look at the top news from the past decade. Throughout the coming months, we'll revisit the most important story from each of the last 10 years and ask: How has practice been affected? With time and perspective, what has changed and what have we learned?
Join Drs Raymond Gibbons, Antonio Colombo, William Boden, Ph Gabriel Steg, and Valentin Fuster for another look at the COURAGE trial, as they discuss the latest data and talk about where things stand now on the larger controversy.
Dr Melissa Walton-Shirley talks to Drs Ph Gabriel Steg and Raymond Gibbons about the differences in STEMI care on both sides of the Atlantic and what US cardiologists can learn from their colleagues in Europe.
Drs Antonio Colombo and Renu Virmani talk about the one-year results of the SYNTAX trial, the importance of understanding registries, and the complex issue of clopidogrel duration with drug-eluting stents in a discussion moderated by heartwire journalist Shelley Wood.
Dr Gregg Stone talks to Drs Keith Fox and Gilles Montalescot about the implications of the DES meta-analysis and the interventional cardiology late-breaking trials presented at the joint SCAI-ACC i2 2008 Scientific Sessions.
Drs Keith Fox and Gregg Stone go into the details of this practice-changing trial as they address concerns about acute stent thrombosis and talk about ways to improve outcomes, in a discussion moderated by Dr James Ferguson.
Debate continues over drug-eluting stentsDrs Gregg Stone and Renu Virmani share their hopes and concerns for PCI and drug-eluting stents as they weigh in on the COURAGE nuclear substudy and the latest registry data on DES vs BMS in a discussion moderated by heartwire journalist Shelley Wood.
PLATO, CURRENT-OASIS 7, and further analyses of PPIs and thienopyridines; read Dr Prasad's review of recent data presented at ESC; and watch presentations by Drs Mehran, O'Donoghue, Storey, and Wiviott.
PLATO, CURRENT-OASIS 7, COGENT, recent meetings have seen some blockbuster presentations in the area of antiplatelet/antithrombotic therapy. What is your response to these data? Answer our 4 short polling questions and learn your peers' responses.
Patients presenting with STEMI represent a high-risk population. Thrombotic and bleeding complications contribute to mortality in these patients. Join Drs. Steg, Hamm, Hill, and Mehran as they discuss best practices for the treatment of STEMI patients with a focus on preventing bleeding complications.
In the US, each year over 1.4 million people will be hospitalized for unstable angina (UA) and non-ST-segment-elevation myocardial infarction (NSTEMI). Multiple antiplatelet agents have been developed to interfere with or inhibit the specific pathways of platelet activation and aggregation that lead to the development of UA and NSTEMI. Join Drs Newby, Popma, and Wiviot as they discuss.
Management of long-term anticoagulation therapy in STEMI patients is challenging. Please join our expert panel, Drs. Elaine Hylek, Ander Cohen, Greg Lip, and Jack Ansell, as they discuss current challenges and strategies to optimize the benefit of and provide insights to the future of anticoagulation therapy.